Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06039449 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
A Phase 3 study, sponsored by Invivyd.
- Completed
- Registry status
- Phase 3
- Development phase
- 790
- Enrollment target
NCT06039449: Completed Phase 3 study, sponsored by Invivyd.
NCT06039449 is a Phase 3 study that has completed, run by Invivyd. The registered enrollment target is 790 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06039449, a Phase 3 study, has completed, sponsored by Invivyd.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 790 participants
- Enrollment target
Study Summary
A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2
Interventions
- DRUG Normal saline
- DRUG VYD222 (pemivibart)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 790 participants |
| Start Date | 2023-09-08 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 3 |
What the finished NCT06039449 record still lists
NCT06039449 is an interventional study that assigns participants to a tested intervention. The registered 790 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT06039449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06039449 about?
NCT06039449 is a clinical study titled "A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2". A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2
What is the current status of trial NCT06039449?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 790 participants. The study started on 2023-09-08. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT06039449?
The interventions under investigation include: Normal saline (DRUG), VYD222 (pemivibart) (DRUG).
Who is sponsoring clinical trial NCT06039449?
This trial is sponsored by Invivyd, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06039449's enrollment target sits among peer trials
790 429th of 2000 higher than 1,570 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
- NCT06162611 · 790 participants · Phase 4
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- NCT05866081 · 792 participants · NA
Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI